Hub : Traits :

Bipolar Disorder or Schizophrenia

972 significantly associated models · 245 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 43476957 45088053 1 1 2.5e-07 8.7e-10 1.4e-04 61 ST3GAL3
2 1 149672809 151435941 7 1 3.5e-11 1.0e-11 1.0e+00 100 PLEKHO1
3 1 154219485 155625602 1 1 2.1e-07 4.4e-07 3.4e-01 96 PBXIP1
4 1 242590540 244359621 3 1 1.1e-10 7.0e-09 2.2e-03 72 CEP170
5 2 26635328 28038799 1 1 8.2e-08 2.6e-08 1.1e-05 38 CGREF1
6 2 73005579 74383630 1 1 1.7e-07 5.6e-08 9.8e-02 91 ALMS1-IT1
7 2 96669134 98622697 4 2 4.4e-11 1.7e-10 1.0e+00 100 LMAN2L TMEM127
8 2 197134790 199259516 5 2 1.6e-11 6.6e-11 1.1e-01 94 ANKRD44 HSPD1
9 2 200086752 202078494 4 1 1.7e-13 7.3e-13 9.5e-02 95 C2orf47
10 2 207747657 209182548 2 1 1.2e-07 1.8e-07 1.0e+00 100 METTL21A
11 2 224636490 226142508 1 1 1.5e-07 2.2e-06 2.1e-01 93 CUL3
12 2 233227833 234123010 3 2 2.3e-10 1.8e-11 1.0e+00 100 EFHD1 NGEF
13 3 1442951 3792945 1 1 5.1e-10 2.4e-12 9.8e-06 60 CNTN4
14 3 36176466 37914922 3 1 1.1e-13 1.0e-18 7.7e-12 40 LRRFIP2
15 3 51616334 54077726 18 1 4.8e-15 3.8e-13 2.3e-01 97 ITIH4-AS1
16 3 63121945 64546545 1 1 2.2e-09 5.0e-09 3.1e-01 97 THOC7
17 3 132509832 133350222 1 1 2.3e-07 9.3e-07 2.6e-01 95 TMEM108
18 5 44129083 45516364 2 1 6.9e-08 1.2e-08 2.6e-02 85 RP11-53O19.3
19 5 59474215 60936935 1 1 9.5e-09 2.3e-11 1.9e-04 69 ERCC8
20 5 136972187 138474788 3 1 1.4e-12 2.7e-10 2.4e-01 97 FAM53C
21 5 139232299 141087689 9 1 7.2e-09 2.0e-07 4.6e-01 98 IK
22 6 24300846 24891985 1 1 1.1e-07 3.2e-05 8.0e-02 82 KIAA0319
23 6 25285943 26689223 2 2 7.5e-12 1.3e-21 1.3e-08 65 TRIM38 U91328.21
24 6 42946943 43582584 2 2 7.1e-09 9.5e-08 1.0e+00 100 C6orf108 ZNF318
25 6 83228260 84829622 2 1 4.4e-13 3.1e-12 4.0e-01 99 SNAP91
26 7 1161158 2977732 2 1 9.3e-10 1.1e-12 1.5e-04 72 FTSJ2
27 7 20767954 22254276 1 1 2.4e-07 7.2e-07 2.3e-01 94 SP4
28 7 24040297 25508637 1 1 1.9e-08 1.1e-10 1.4e-03 76 DFNA5
29 7 86535446 87065687 1 1 1.4e-07 2.3e-07 1.1e-01 90 DMTF1
30 8 25544268 26938804 1 1 1.1e-07 5.1e-08 1.0e+00 100 SDAD1P1
31 8 37329315 38932193 7 1 4.5e-11 8.4e-09 2.7e-01 96 PPAPDC1B
32 8 142839492 144323692 2 1 6.6e-08 1.2e-11 1.1e-06 48 BAI1
33 10 101744428 102275727 1 1 2.2e-07 2.3e-05 7.5e-01 99 CWF19L1
34 10 103313599 105647095 14 1 8.5e-19 6.0e-16 4.9e-01 99 AS3MT
35 11 62922117 64707978 3 1 2.0e-14 3.1e-09 3.8e-02 88 PPP1R14B
36 11 65405300 67324933 11 1 7.0e-10 2.9e-09 7.4e-01 100 CTD-3074O7.5
37 12 1204676 2805632 2 2 5.5e-17 3.3e-20 1.5e-04 83 CACNA2D4 DCP1B
38 12 122713991 124591385 10 1 2.7e-10 4.8e-10 1.0e+00 100 CDK2AP1
39 14 71126913 71826787 1 1 2.9e-07 1.7e-06 8.9e-01 100 PCNX
40 14 103161201 105211221 12 1 3.4e-13 2.3e-12 1.4e-01 96 PPP1R13B
41 15 78135979 79537269 2 1 7.5e-12 1.8e-11 1.0e+00 100 CHRNA5
42 15 83167559 83804861 2 1 7.0e-09 9.5e-08 6.8e-01 99 CPEB1
43 15 84151637 86489699 13 1 3.3e-15 1.8e-14 2.9e-01 98 AC103965.1
44 15 90718541 92135418 3 1 4.9e-15 2.5e-13 4.1e-02 92 FES
45 16 28825605 31026427 17 1 2.7e-11 6.8e-11 6.1e-02 92 MAPK3
46 16 57850605 59241430 1 1 3.8e-08 2.7e-08 1.2e-01 92 SETD6
47 16 67351698 70136868 4 2 2.9e-08 2.3e-07 2.3e-01 95 DUS2 TERF2
48 16 73971308 75396376 1 1 2.3e-07 5.0e-06 1.6e-02 72 RFWD3
49 16 88858246 90172696 4 1 3.1e-08 1.4e-06 1.9e-02 76 SPATA33
50 17 12647408 13160648 1 1 1.5e-07 1.8e-06 7.0e-01 99 ELAC2
51 17 18051975 20017091 6 2 2.8e-09 2.1e-07 2.2e-01 94 GRAP PRPSAP2
52 19 18408222 20451172 12 2 2.6e-11 7.1e-10 6.8e-01 100 LPAR2 SUGP2
53 20 36681910 38094711 1 1 2.5e-09 2.6e-10 7.7e-04 72 ACTR5
54 20 42924921 44408428 1 1 2.6e-09 2.4e-09 1.0e+00 100 STK4
55 20 49333081 49817847 1 1 2.5e-07 2.2e-08 9.7e-03 79 MOCS3
56 22 21798199 23032448 4 1 1.6e-09 3.7e-08 9.5e-01 100 LL22NC03-86G7.1
57 22 39192995 43232818 15 3 1.0e-11 1.6e-10 2.6e-04 67 MGAT3 NAGA XPNPEP3

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Bipolar Disorder (2018) 8.10 19 7 15.6 1.00 1.0e-18 AC103965.1 CACNA2D4 CTD-3074O7.5 DFNA5 ITIH4-AS1 LL22NC03-86G7.1 LMAN2L LPAR2 LRRFIP2 MAPK3 PLEKHO1 PPAPDC1B PPP1R14B PRPSAP2 SNAP91 SPATA33 STK4 SUGP2 XPNPEP3
Depressed Affect (Nagel 2018) 1.60 1 0 0.0 0.00 1.0e+00 STK4
Intelligence (Savage-Jansen 2018) 2.48 8 4 8.9 -0.74 3.6e-02 ALMS1-IT1 C6orf108 CDK2AP1 CWF19L1 IK ITIH4-AS1 MGAT3 ST3GAL3
Neuroticism (Nagel 2018) 1.68 3 0 0.0 0.00 1.0e+00 AS3MT SP4 SUGP2
Schizophrenia (2018) 13.28 61 29 64.4 0.99 4.4e-51 AC103965.1 ACTR5 ALMS1-IT1 ANKRD44 AS3MT BAI1 C2orf47 C6orf108 CACNA2D4 CDK2AP1 CEP170 CGREF1 CHRNA5 CNTN4 CPEB1 CTD-3074O7.5 CUL3 CWF19L1 DCP1B DMTF1 DUS2 EFHD1 ELAC2 ERCC8 FAM53C FES FTSJ2 GRAP HSPD1 IK ITIH4-AS1 KIAA0319 LMAN2L LPAR2 LRRFIP2 MAPK3 METTL21A MGAT3 NAGA NGEF PCNX PLEKHO1 PPAPDC1B PPP1R13B PPP1R14B PRPSAP2 RFWD3 RP11-53O19.3 SDAD1P1 SETD6 SNAP91 SP4 ST3GAL3 SUGP2 TERF2 THOC7 TMEM127 TRIM38 U91328.21 XPNPEP3 ZNF318
Worry (Nagel 2018) 2.22 5 2 4.4 0.99 1.4e-03 AS3MT C2orf47 ITIH4-AS1 SUGP2 XPNPEP3
Reaction Time 1.57 3 0 0.0 0.00 1.0e+00 C2orf47 NGEF SNAP91
Verbal and Numeric Reasoning (VNR) 2.69 8 2 4.4 -0.76 2.7e-02 ALMS1-IT1 CDK2AP1 IK ITIH4-AS1 MGAT3 NAGA ST3GAL3 U91328.21
Breast Cancer 2.78 5 2 4.4 -0.90 3.7e-02 C6orf108 FES LPAR2 RP11-53O19.3 SUGP2
Ovarian Cancer 1.28 1 0 0.0 0.00 1.0e+00 DUS2
Prostate Cancer 1.74 1 0 0.0 0.00 1.0e+00 PBXIP1
Bipolar Disorder (2011) 6.55 5 0 0.0 0.99 1.0e-03 CACNA2D4 CTD-3074O7.5 ITIH4-AS1 LMAN2L SNAP91
Coronary Artery Disease (CAD) 1.33 1 0 0.0 0.00 1.0e+00 AS3MT
Fasting Glucose 1.67 1 1 2.2 0.00 1.0e+00 CGREF1
HDL Cholesterol 0.86 1 1 2.2 0.00 1.0e+00 DUS2
Schizophrenia (2014) 13.10 60 33 73.3 0.99 1.3e-51 AC103965.1 ACTR5 ALMS1-IT1 ANKRD44 AS3MT BAI1 C2orf47 C6orf108 CACNA2D4 CDK2AP1 CEP170 CGREF1 CHRNA5 CNTN4 CPEB1 CUL3 CWF19L1 DCP1B DMTF1 DUS2 EFHD1 ELAC2 ERCC8 FAM53C FES FTSJ2 GRAP HSPD1 IK ITIH4-AS1 KIAA0319 LL22NC03-86G7.1 LMAN2L LPAR2 LRRFIP2 MAPK3 METTL21A MGAT3 MOCS3 NAGA NGEF PBXIP1 PCNX PLEKHO1 PPAPDC1B PPP1R13B PPP1R14B PRPSAP2 RFWD3 RP11-53O19.3 SETD6 SNAP91 SPATA33 ST3GAL3 STK4 SUGP2 THOC7 TMEM127 XPNPEP3 ZNF318
Triglycerides 1.05 1 1 2.2 0.00 1.0e+00 CGREF1
Blood Eosinophil Count 1.11 11 6 13.3 0.19 5.8e-01 AC103965.1 CDK2AP1 ITIH4-AS1 LMAN2L LPAR2 MAPK3 PBXIP1 PRPSAP2 SUGP2 TMEM127 XPNPEP3
Blood Platelet Count 0.98 10 7 15.6 0.00 9.9e-01 ANKRD44 CDK2AP1 CGREF1 DFNA5 HSPD1 ITIH4-AS1 KIAA0319 LPAR2 ST3GAL3 SUGP2
Blood Red Count 1.47 13 9 20.0 0.30 3.2e-01 ANKRD44 C2orf47 C6orf108 CDK2AP1 CTD-3074O7.5 DUS2 ITIH4-AS1 LL22NC03-86G7.1 LPAR2 MAPK3 SDAD1P1 ST3GAL3 SUGP2
Blood White Count 0.63 4 4 8.9 -1.00 4.4e-03 FES MGAT3 PPP1R13B THOC7
Heel T-Score 1.04 7 4 8.9 0.59 1.6e-01 CDK2AP1 CWF19L1 MAPK3 NGEF PLEKHO1 PPP1R13B TMEM127
BMI 1.68 9 5 11.1 -0.60 8.6e-02 AS3MT BAI1 C2orf47 CTD-3074O7.5 ITIH4-AS1 MAPK3 METTL21A PBXIP1 PPP1R13B
Height 1.42 25 17 37.8 0.01 9.6e-01 AC103965.1 AS3MT CDK2AP1 CEP170 CTD-3074O7.5 CWF19L1 DFNA5 EFHD1 FES IK ITIH4-AS1 LL22NC03-86G7.1 LMAN2L LPAR2 MAPK3 MGAT3 NGEF PPAPDC1B PPP1R13B SPATA33 ST3GAL3 STK4 SUGP2 TERF2 THOC7
Waist Hip Ratio (WHR) 1.92 10 2 4.4 -0.01 9.9e-01 AC103965.1 C6orf108 CDK2AP1 CGREF1 DUS2 ERCC8 FAM53C ITIH4-AS1 MGAT3 PCNX
Systolic Blood Pressure 2.43 8 7 15.6 -0.23 5.9e-01 AS3MT C2orf47 DFNA5 FES IK PCNX PPAPDC1B PPP1R14B
Smoking Status 2.31 6 3 6.7 0.24 6.5e-01 AS3MT ERCC8 FES PPP1R13B SNAP91 ST3GAL3
Allergy or Eczema 1.64 3 2 4.4 0.00 1.0e+00 ANKRD44 CDK2AP1 HSPD1
Cardiovascular Disease 1.99 4 2 4.4 -0.20 8.0e-01 AS3MT FES PCNX PPP1R13B
Hypothyroidism (self reported) 1.22 1 0 0.0 0.00 1.0e+00 DUS2
Respiratory disease 1.33 2 0 0.0 0.00 1.0e+00 ANKRD44 SPATA33
Lung FEV1/FVC ratio 1.35 6 3 6.7 -0.57 2.4e-01 AC103965.1 CHRNA5 DUS2 GRAP ITIH4-AS1 RP11-53O19.3
Lung FVC 1.13 7 2 4.4 -0.36 4.3e-01 CHRNA5 CUL3 EFHD1 FTSJ2 IK PLEKHO1 PPAPDC1B
Neuroticism 1.59 2 1 2.2 0.00 1.0e+00 AS3MT SP4
Chronotype (morning person) 1.93 2 2 4.4 0.00 1.0e+00 CTD-3074O7.5 TMEM108
Hair Pigment 6.64 10 7 15.6 -0.27 4.5e-01 CDK2AP1 CPEB1 EFHD1 FAM53C FES PCNX PLEKHO1 PPP1R13B SPATA33 XPNPEP3
Tanning 7.35 3 1 2.2 0.00 1.0e+00 ERCC8 ITIH4-AS1 SPATA33
Hand grip strength (left) 1.28 4 0 0.0 0.14 8.6e-01 AS3MT FES MAPK3 SNAP91
Number of treatments/medications taken 1.34 1 0 0.0 0.00 1.0e+00 FES
Sensitivity / hurt feelings 1.45 2 1 2.2 0.00 1.0e+00 FES SUGP2
Relative age of first facial hair 1.13 1 1 2.2 0.00 1.0e+00 SPATA33
Systolic blood pressure, automated reading 2.04 4 2 4.4 -0.34 6.6e-01 AS3MT FES PPAPDC1B PPP1R14B
Angina 1.55 1 1 2.2 0.00 1.0e+00 FES
Pack years adult smoking proportion 3.65 2 1 2.2 0.00 1.0e+00 CHRNA5 PPP1R13B
Impedance of leg (right) 2.69 12 10 22.2 0.10 7.6e-01 AC103965.1 AS3MT C2orf47 CTD-3074O7.5 ERCC8 FES ITIH4-AS1 MAPK3 PBXIP1 PPAPDC1B PPP1R13B SUGP2
Leg fat-free mass (left) 1.91 11 5 11.1 -0.31 3.6e-01 AS3MT C2orf47 CDK2AP1 EFHD1 ERCC8 FES MAPK3 METTL21A MGAT3 PBXIP1 PPAPDC1B
Trunk fat percentage 1.39 5 3 6.7 -0.53 3.6e-01 AC103965.1 ANKRD44 CGREF1 MAPK3 RFWD3
Current tobacco smoking 2.13 6 0 0.0 0.50 3.1e-01 AS3MT CHRNA5 CUL3 METTL21A PPP1R13B ST3GAL3
Maternal smoking around birth 1.96 3 1 2.2 0.00 1.0e+00 AS3MT CHRNA5 PPP1R13B
Age when periods started (menarche) 1.51 2 1 2.2 0.00 1.0e+00 MAPK3 ST3GAL3
Heel bone mineral density (BMD) T-score, automated (left) 0.91 1 0 0.0 0.00 1.0e+00 NGEF
High blood pressure 2.32 3 1 2.2 0.00 1.0e+00 FES PCNX SPATA33
Hayfever, allergic rhinitis or eczema 1.38 2 2 4.4 0.00 1.0e+00 ANKRD44 HSPD1
Multivitamins +/- minerals 1.77 1 0 0.0 0.00 1.0e+00 BAI1
Medication: Atenolol 1.55 1 1 2.2 0.00 1.0e+00 FES
Sitting height 1.67 12 7 15.6 0.01 9.7e-01 AC103965.1 CDK2AP1 EFHD1 FAM53C IK LPAR2 MGAT3 NGEF SUGP2 TERF2 THOC7 TRIM38
Chronic bronchitis/emphysema (father) 1.67 1 1 2.2 0.00 1.0e+00 CHRNA5
High blood pressure (mother) 2.34 1 1 2.2 0.00 1.0e+00 FES
Body mass index (BMI) 1.56 7 4 8.9 -0.51 2.4e-01 AS3MT BAI1 C2orf47 CTD-3074O7.5 ITIH4-AS1 MAPK3 PPP1R13B
Impedance of leg (left) 2.59 12 10 22.2 -0.01 9.8e-01 AC103965.1 AS3MT CDK2AP1 CTD-3074O7.5 ERCC8 FES ITIH4-AS1 MAPK3 PBXIP1 PPAPDC1B PPP1R13B SUGP2
Leg predicted mass (left) 1.92 11 5 11.1 -0.31 3.6e-01 AS3MT C2orf47 CDK2AP1 EFHD1 ERCC8 FES MAPK3 METTL21A MGAT3 PBXIP1 PPAPDC1B
Trunk fat mass 1.52 7 3 6.7 -0.78 4.0e-02 AC103965.1 AS3MT C2orf47 EFHD1 MAPK3 RFWD3 TRIM38
Waist circumference 1.64 5 1 2.2 -0.70 1.9e-01 AS3MT BAI1 C2orf47 MAPK3 PPP1R13B
Number of incorrect matches in round 2.40 4 1 2.2 -0.29 7.1e-01 AS3MT C6orf108 FES MAPK3
Past tobacco smoking 1.70 1 1 2.2 0.00 1.0e+00 AS3MT
Alcohol usually taken with meals 1.90 1 0 0.0 0.00 1.0e+00 FES
Nervous feelings 1.85 2 2 4.4 0.00 1.0e+00 AS3MT ITIH4-AS1
Hearing difficulty/problems with background noise 1.57 1 0 0.0 0.00 1.0e+00 ZNF318
Forced vital capacity (FVC) 1.29 8 1 2.2 -0.18 6.8e-01 AC103965.1 CEP170 CHRNA5 CUL3 IK PLEKHO1 TERF2 U91328.21
Heel bone mineral density (BMD) T-score, automated (right) 0.97 2 0 0.0 0.00 1.0e+00 KIAA0319 NGEF
Qualifications: None of the above 2.05 4 3 6.7 0.43 5.7e-01 CDK2AP1 DFNA5 ERCC8 ST3GAL3
Financial difficulties in last 2 years 1.29 1 1 2.2 0.00 1.0e+00 PPP1R13B
Mouth/teeth dental problems 1.30 1 0 0.0 0.00 1.0e+00 PPP1R13B
Heart attack 1.32 1 1 2.2 0.00 1.0e+00 FES
Allergy 1.50 5 2 4.4 -0.61 2.8e-01 ANKRD44 CDK2AP1 CTD-3074O7.5 FES HSPD1
Medication: Ramipril 1.65 1 0 0.0 0.00 1.0e+00 FES
Medication: Simvastatin 1.65 1 1 2.2 0.00 1.0e+00 FES
Fluid intelligence score 2.35 6 2 4.4 -0.66 1.5e-01 ALMS1-IT1 CDK2AP1 CGREF1 MGAT3 ST3GAL3 U91328.21
Illnesses of siblings 1.13 1 1 2.2 0.00 1.0e+00 FES
Weight 1.73 7 3 6.7 -0.44 3.2e-01 AC103965.1 AS3MT C2orf47 CDK2AP1 EFHD1 MAPK3 TRIM38
Impedance of arm (right) 2.18 12 6 13.3 0.56 5.8e-02 AC103965.1 ANKRD44 ERCC8 FAM53C HSPD1 ITIH4-AS1 LPAR2 MAPK3 PBXIP1 PPAPDC1B SNAP91 SUGP2
Arm fat percentage (right) 1.20 4 1 2.2 -0.06 9.4e-01 CTD-3074O7.5 MAPK3 PPP1R13B RFWD3
Trunk fat-free mass 1.80 11 6 13.3 -0.36 2.7e-01 AS3MT CDK2AP1 EFHD1 ERCC8 FAM53C HSPD1 MAPK3 METTL21A MGAT3 PBXIP1 PPAPDC1B
Hip circumference 1.64 7 2 4.4 -0.52 2.3e-01 AC103965.1 AS3MT BAI1 CDK2AP1 EFHD1 ITIH4-AS1 MAPK3
Father's age at death 1.49 2 2 4.4 0.00 1.0e+00 CHRNA5 FES
Worrier / anxious feelings 2.32 4 2 4.4 0.99 1.2e-02 AS3MT C2orf47 CACNA2D4 ITIH4-AS1
Frequency of tiredness / lethargy in last 2 weeks 1.69 1 0 0.0 0.00 1.0e+00 PPP1R13B
Forced expiratory volume in 1-second (FEV1) 1.51 5 4 8.9 -0.18 7.7e-01 AC103965.1 CEP170 CHRNA5 PLEKHO1 U91328.21
Pulse rate 1.37 1 0 0.0 0.00 1.0e+00 ITIH4-AS1
Qualifications: A levels/AS levels or equivalent 2.22 5 2 4.4 -0.27 6.7e-01 CDK2AP1 DFNA5 ERCC8 MGAT3 ST3GAL3
Mouth/teeth dental problems: Dentures 1.83 2 0 0.0 0.00 1.0e+00 CHRNA5 TRIM38
Asthma 1.61 2 0 0.0 0.00 1.0e+00 SPATA33 U91328.21
Medication: Ibuprofen (e.g. Nurofen) 1.31 1 0 0.0 0.00 1.0e+00 U91328.21
Medication: Cholesterol lowering 1.56 1 1 2.2 0.00 1.0e+00 FES
Lung cancer (father) 1.71 1 1 2.2 0.00 1.0e+00 CHRNA5
Illnesses of mother 1.60 1 1 2.2 0.00 1.0e+00 FES
Forced expiratory volume in 1-second (FEV1), Best measure 1.37 6 3 6.7 -0.25 6.3e-01 AC103965.1 CEP170 CHRNA5 IK PLEKHO1 U91328.21
Impedance of arm (left) 2.19 12 6 13.3 0.54 7.1e-02 AC103965.1 ANKRD44 CGREF1 ERCC8 HSPD1 ITIH4-AS1 LPAR2 MAPK3 PPAPDC1B PRPSAP2 SNAP91 SUGP2
Arm fat mass (right) 1.45 5 1 2.2 -0.71 1.8e-01 AS3MT C2orf47 MAPK3 PPP1R13B RFWD3
Trunk predicted mass 1.80 10 6 13.3 -0.35 3.3e-01 AS3MT CDK2AP1 EFHD1 ERCC8 HSPD1 MAPK3 METTL21A MGAT3 PBXIP1 PPAPDC1B
Standing height 1.34 11 8 17.8 -0.02 9.5e-01 AC103965.1 AS3MT CDK2AP1 CTD-3074O7.5 EFHD1 IK ITIH4-AS1 LPAR2 MAPK3 NGEF TERF2
Tense / 'highly strung' 1.75 1 0 0.0 0.00 1.0e+00 CACNA2D4
Seen doctor (GP) for nerves, anxiety, tension or depression 2.09 2 0 0.0 0.00 1.0e+00 CTD-3074O7.5 U91328.21
Hair/balding pattern: Pattern 4 0.77 1 0 0.0 0.00 1.0e+00 SPATA33
Birth weight of first child 1.70 2 1 2.2 0.00 1.0e+00 AS3MT FES
Qualifications: O levels/GCSEs or equivalent 2.05 2 1 2.2 0.00 1.0e+00 CDK2AP1 DFNA5
Medication: Paracetamol 2.20 1 1 2.2 0.00 1.0e+00 U91328.21
Headache pain in last month 1.67 2 2 4.4 0.00 1.0e+00 CEP170 U91328.21
Medication for cholesterol, blood pressure or diabetes 1.99 1 1 2.2 0.00 1.0e+00 FES
Gout (self-reported) 1.35 1 0 0.0 0.00 1.0e+00 PBXIP1
Medication: Amlodipine 1.44 1 1 2.2 0.00 1.0e+00 FES
Birth weight 1.70 3 1 2.2 0.00 1.0e+00 AS3MT DUS2 FES
Chronic bronchitis/emphysema (mother) 1.40 1 1 2.2 0.00 1.0e+00 CHRNA5
High blood pressure (siblings) 1.37 1 1 2.2 0.00 1.0e+00 FES
Forced vital capacity (FVC), Best measure 1.15 6 2 4.4 -0.19 7.1e-01 AC103965.1 CEP170 CUL3 IK TERF2 U91328.21
Body fat percentage 1.28 5 3 6.7 -0.54 3.4e-01 AC103965.1 ANKRD44 CGREF1 MAPK3 RFWD3
Leg fat percentage (right) 1.14 3 1 2.2 0.00 1.0e+00 AC103965.1 MAPK3 RFWD3
Arm fat-free mass (right) 1.94 11 5 11.1 -0.40 2.2e-01 AS3MT CDK2AP1 EFHD1 ERCC8 FAM53C HSPD1 MAPK3 METTL21A MGAT3 PBXIP1 PPAPDC1B
Comparative body size at age 10 1.77 7 0 0.0 -0.99 3.4e-05 C6orf108 ERCC8 LL22NC03-86G7.1 LPAR2 MAPK3 SUGP2 U91328.21
Qualifications: College or University degree 2.47 8 5 11.1 0.01 9.9e-01 ALMS1-IT1 CDK2AP1 DFNA5 ERCC8 MGAT3 SDAD1P1 ST3GAL3 STK4
Medication for pain relief, constipation, heartburn 2.11 3 1 2.2 0.00 1.0e+00 CDK2AP1 PCNX U91328.21
Medication: Blood pressure 2.11 1 1 2.2 0.00 1.0e+00 FES
Angina (self-reported) 1.55 1 1 2.2 0.00 1.0e+00 FES
Medication: Allopurinol 1.45 1 0 0.0 0.00 1.0e+00 PBXIP1
Mean time to correctly identify matches 1.53 1 0 0.0 0.00 1.0e+00 SNAP91
Whole body fat mass 1.50 5 3 6.7 -0.94 1.6e-02 AC103965.1 AS3MT C2orf47 MAPK3 RFWD3
Leg fat mass (right) 1.43 4 2 4.4 -0.92 8.0e-02 AC103965.1 AS3MT MAPK3 RFWD3
Arm predicted mass (right) 1.89 10 4 8.9 -0.40 2.5e-01 AS3MT CDK2AP1 EFHD1 ERCC8 HSPD1 MAPK3 METTL21A MGAT3 PBXIP1 PPAPDC1B
Pulse rate, automated reading 1.48 3 2 4.4 0.00 1.0e+00 EFHD1 ITIH4-AS1 RP11-53O19.3
Alcohol intake frequency. 1.24 5 0 0.0 0.01 9.9e-01 BAI1 CDK2AP1 CGREF1 CHRNA5 TERF2
Comparative height size at age 10 1.61 9 5 11.1 0.28 4.6e-01 AC103965.1 CDK2AP1 EFHD1 FES ITIH4-AS1 LL22NC03-86G7.1 MAPK3 ST3GAL3 U91328.21
Suffer from 'nerves' 1.30 1 0 0.0 0.00 1.0e+00 AS3MT
Overall health rating 1.49 1 0 0.0 0.00 1.0e+00 CGREF1
Medication: Aspirin 1.31 1 1 2.2 0.00 1.0e+00 FES
Hypertension (Self-reported) 2.33 3 2 4.4 0.00 1.0e+00 FES PPP1R14B SPATA33
Illnesses of father: Heart disease 1.82 1 1 2.2 0.00 1.0e+00 FES
Forced expiratory volume in 1-second (FEV1), predicted 1.34 1 1 2.2 0.00 1.0e+00 AC103965.1
Whole body fat-free mass 1.90 9 5 11.1 -0.35 3.6e-01 AS3MT CDK2AP1 EFHD1 ERCC8 MAPK3 METTL21A MGAT3 PBXIP1 PPAPDC1B
Leg fat-free mass (right) 1.95 13 5 11.1 -0.35 2.4e-01 AS3MT C2orf47 CDK2AP1 CEP170 EFHD1 ERCC8 FES MAPK3 METTL21A MGAT3 PBXIP1 PPAPDC1B STK4
Arm fat percentage (left) 1.19 5 1 2.2 -0.57 3.1e-01 ANKRD44 C2orf47 MAPK3 PPP1R13B RFWD3
Average weekly red wine intake 1.23 1 0 0.0 0.00 1.0e+00 CDK2AP1
Qualifications: nursing, teaching 1.77 2 1 2.2 0.00 1.0e+00 CDK2AP1 ERCC8
Medication for cholesterol 1.32 1 0 0.0 0.00 1.0e+00 FES
Medication: Laxatives (e.g. Dulcolax, Senokot) 1.28 1 0 0.0 0.00 1.0e+00 CGREF1
Asthma (self-reported) 1.60 2 0 0.0 0.00 1.0e+00 SPATA33 U91328.21
Medication: Aspirin 1.46 1 1 2.2 0.00 1.0e+00 FES
Illnesses of father: None of the above (group 1) 1.74 1 1 2.2 0.00 1.0e+00 FES
Smoking status: Current 2.11 5 1 2.2 0.44 4.6e-01 AS3MT CUL3 METTL21A PPP1R13B ST3GAL3
Forced expiratory volume in 1-second (FEV1), predicted percentage 1.68 3 2 4.4 0.00 1.0e+00 CHRNA5 PLEKHO1 U91328.21
Whole body water mass 1.92 10 6 13.3 -0.36 3.0e-01 AS3MT CDK2AP1 CEP170 EFHD1 ERCC8 MAPK3 METTL21A MGAT3 PBXIP1 PPAPDC1B
Leg predicted mass (right) 1.96 12 5 11.1 -0.33 3.0e-01 AS3MT C2orf47 CDK2AP1 CEP170 EFHD1 ERCC8 FES MAPK3 METTL21A MGAT3 PBXIP1 PPAPDC1B
Arm fat mass (left) 1.53 6 2 4.4 -0.74 9.3e-02 AS3MT BAI1 C2orf47 MAPK3 PPP1R13B RFWD3
Average weekly champagne plus white wine intake 1.39 1 0 0.0 0.00 1.0e+00 EFHD1
Miserableness 1.43 1 0 0.0 0.00 1.0e+00 CEP170
Guilty feelings 1.62 1 0 0.0 0.00 1.0e+00 KIAA0319
Hearing aid user 1.29 1 0 0.0 0.00 1.0e+00 ERCC8
Medication: Blood pressure 1.75 2 1 2.2 0.00 1.0e+00 FES SPATA33
High cholesterol (Self-reported) 1.38 1 0 0.0 0.00 1.0e+00 CGREF1
Medication: Bendroflumethiazide 1.34 1 1 2.2 0.00 1.0e+00 FES
Medication: Paracetamol 2.01 1 0 0.0 0.00 1.0e+00 U91328.21
Illnesses of father: High blood pressure 2.29 1 1 2.2 0.00 1.0e+00 FES
Ever smoked 1.94 2 0 0.0 0.00 1.0e+00 AS3MT CDK2AP1
Basal metabolic rate 1.89 12 4 8.9 -0.46 1.3e-01 AS3MT C2orf47 CDK2AP1 CEP170 EFHD1 ERCC8 IK MAPK3 METTL21A MGAT3 PBXIP1 PPAPDC1B
Leg fat percentage (left) 1.17 3 1 2.2 0.00 1.0e+00 AC103965.1 MAPK3 RFWD3
Arm fat-free mass (left) 1.93 10 4 8.9 -0.40 2.5e-01 AS3MT CDK2AP1 EFHD1 ERCC8 FTSJ2 HSPD1 MAPK3 METTL21A MGAT3 PPAPDC1B
Number of operations (self-reported) 1.37 1 0 0.0 0.00 1.0e+00 ERCC8
Risk taking 2.89 2 1 2.2 0.00 1.0e+00 CEP170 PPP1R13B
Diastolic blood pressure, automated reading 2.58 6 5 11.1 -0.58 2.2e-01 ALMS1-IT1 CDK2AP1 CEP170 FES TMEM127 U91328.21
Vascular/heart problems diagnosed by doctor 2.44 3 1 2.2 0.00 1.0e+00 FES PCNX SPATA33
Basal cell carcinoma (self-reported) 1.49 1 1 2.2 0.00 1.0e+00 SPATA33
Heart attack/myocardial infarction (self-reported) 1.29 1 1 2.2 0.00 1.0e+00 FES
Heart disease (siblings) 1.09 1 0 0.0 0.00 1.0e+00 FES
Alcohol drinker status: Previous 1.38 1 0 0.0 0.00 1.0e+00 PPP1R13B
Pack years of smoking 3.29 1 1 2.2 0.00 1.0e+00 CHRNA5
Impedance of whole body 2.58 14 11 24.4 0.35 2.2e-01 AC103965.1 ANKRD44 AS3MT CTD-3074O7.5 ERCC8 FTSJ2 HSPD1 ITIH4-AS1 LPAR2 MAPK3 PBXIP1 PPAPDC1B PPP1R13B SUGP2
Leg fat mass (left) 1.47 6 2 4.4 -0.93 7.6e-03 AC103965.1 AS3MT C2orf47 MAPK3 RFWD3 TRIM38
Arm predicted mass (left) 1.89 9 4 8.9 -0.33 3.9e-01 AS3MT CDK2AP1 EFHD1 ERCC8 HSPD1 MAPK3 METTL21A MGAT3 PPAPDC1B

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 19 0.56 2.5
GTEx Adipose Visceral Omentum 12 0.61 2.6
GTEx Adrenal Gland 9 0.63 2.4
GTEx Artery Aorta 21 0.73 2.6
GTEx Artery Coronary 6 0.52 2.5
GTEx Artery Tibial 29 0.80 2.6
GTEx Brain Caudate basal ganglia 3 0.33 2.5
GTEx Brain Cerebellar Hemisphere 9 0.62 2.5
GTEx Brain Cerebellum 15 0.77 2.8
GTEx Brain Cortex 7 0.69 2.7
GTEx Brain Frontal Cortex BA9 2 0.22 2.4
GTEx Brain Hippocampus 6 1.17 2.6
GTEx Brain Hypothalamus 4 0.70 2.4
GTEx Brain Nucleus accumbens basal ganglia 6 0.71 2.6
GTEx Brain Putamen basal ganglia 3 0.49 2.3
GTEx Breast Mammary Tissue 18 0.94 2.8
GTEx Breast Mammary Tissue (Male) 8 0.70 2.7
GTEx Breast Mammary Tissue (Female) 16 1.02 2.6
GTEx Cells EBV-transformed lymphocytes 12 0.87 2.8
GTEx Cells Transformed fibroblasts 34 0.83 2.6
GTEx Colon Sigmoid 12 0.84 2.6
GTEx Colon Transverse 17 0.85 2.8
GTEx Esophagus Gastroesophageal Junction 9 0.64 2.6
GTEx Esophagus Mucosa 23 0.71 2.6
GTEx Esophagus Muscularis 27 0.86 2.6
GTEx Heart Atrial Appendage 13 0.84 2.7
GTEx Heart Left Ventricle 9 0.61 2.7
GTEx Liver 8 1.14 2.7
GTEx Lung 19 0.68 2.5
GTEx Muscle Skeletal 23 0.82 2.6
GTEx Nerve Tibial 24 0.57 2.5
GTEx Ovary 6 0.68 2.7
GTEx Pancreas 13 0.81 2.8
GTEx Pituitary 11 1.00 2.7
GTEx Prostate 10 1.23 2.9
GTEx Skin Not Sun Exposed Suprapubic 15 0.62 2.6
GTEx Skin Sun Exposed Lower leg 21 0.59 2.6
GTEx Small Intestine Terminal Ileum 4 0.89 2.6
GTEx Spleen 19 1.38 2.7
GTEx Stomach 9 0.64 2.5
GTEx Testis 29 0.94 2.7
GTEx Thyroid 28 0.72 2.6
GTEx Uterus 2 0.36 2.4
GTEx Vagina 4 0.65 2.4
GTEx Whole Blood 16 0.83 2.6
METSIM Adipose 13 0.29 2.3
NTR Blood 12 0.50 2.3
ROSMAP Brain Pre-frontal Cortex 33 0.77 2.6
YFS Blood 24 0.53 2.3
CommonMind Brain Pre-frontal Cortex 28 0.53 2.5
The Cancer Genome Atlas Bladder Urothelial Carcinoma 9 0.57 2.6
The Cancer Genome Atlas Breast Invasive Carcinoma 19 0.45 2.4
The Cancer Genome Atlas Cervical Squamous Cell Carcinoma 6 0.57 2.4
The Cancer Genome Atlas Colon Adenocarcinoma 12 0.61 2.5
The Cancer Genome Atlas Esophageal Carcinoma 2 0.30 2.6
The Cancer Genome Atlas Glioblastoma Multiforme 5 0.52 2.5
The Cancer Genome Atlas Head and Neck Squamous Cell Carcinoma 11 0.42 2.4
The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma 16 0.41 2.4
The Cancer Genome Atlas Kidney Renal Papillary Cell Carcinoma 9 0.46 2.5
The Cancer Genome Atlas Brain Lower Grade Glioma 16 0.39 2.4
The Cancer Genome Atlas Liver Hepatocellular Carcinoma 6 0.56 2.4
The Cancer Genome Atlas Lung Adenocarcinoma 11 0.39 2.4
The Cancer Genome Atlas Lung Squamous Cell Carcinoma 16 0.67 2.6
The Cancer Genome Atlas Ovarian Serous Cystadenocarcinoma 8 0.52 2.5
The Cancer Genome Atlas Pancreatic Adenocarcinoma 10 0.63 2.5
The Cancer Genome Atlas Pheochromocytoma and Paraganglioma 8 0.64 2.5
The Cancer Genome Atlas Prostate Adenocarcinoma 24 0.54 2.4
The Cancer Genome Atlas Rectum Adenocarcinoma 2 0.30 2.3
The Cancer Genome Atlas Soft Tissue Sarcoma 6 0.59 2.5
The Cancer Genome Atlas Skin Cutaneous Melanoma 1 0.20 2.3
The Cancer Genome Atlas Stomach Adenocarcinoma 10 0.62 2.5
The Cancer Genome Atlas Testicular Germ Cell Tumors 6 0.49 2.5
The Cancer Genome Atlas Thyroid Carcinoma 39 0.79 2.5
The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma 0 0.00 2.0